Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.
By J. Bernier, Christian Domenge, M. Ozsahin, K. Matuszewska, J. Lefebvre, R. Greiner, J. Giralt, P. Maingon, F. Rolland, Michel Bolla and 4 more. New England Journal of Medicine, 2004
2,975 citations recorded by the source corpus.
Subfields: Otorhinolaryngology, Pulmonary and Respiratory Medicine, Radiation
View Paper: https://www.semanticscholar.org/paper/cea469b83f379efdebbbe4bcbc1e07eefefcea50
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Otorhinolaryngology
Citations in the corpus
- Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501) (2005, methodology): “First, a previous RTOG study (RTOG 8503), which tested the value of sequential postoperative chemotherapy and radiation therapy,(7) suggested three risk groupings: (1) lowest risk when fewer than two nodes were histologically involved, no ECE was present, and surgical margins were not histologically”
- Advances in Radiation Therapy: Conventional to 3D, to IMRT, to 4D, and Beyond (2005, result): “While it logically follows that if concurrent chemotherapy confers a benefit to radiation in the definitive setting, it would add a similar benefit in the postoperative setting; this had not been shown until the publication of two landmark trials earlier this year.(57,58) Two similar trials, one in ”
- Oral cavity and oropharyngeal squamous cell carcinoma—an update (2015, background): “and the need for adjuvant radiation or chemoradiation therapy often dictated by adverse findings (eg, positive surgical margins, perineural or lymphovascular invasion, N2 or N3 lymph node disease, lymph node disease in levels IV or V, extracapsular extension of tumor in lymph nodes).(174-176) Althou”
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) (2019, background): “Data supported an anti-tumor effect following a single dose of pembrolizumab [160].”